Trial Profile

A Phase II/III study of Intraperitoneal (IP) Plus Intravenous (IV) Chemotherapy Versus IV Carboplatin plus Paclitaxel in Patients with Epithelial Ovarian Cancer Optimally Debulked at Surgery Following Neoadjuvant Intravenous Chemotherapy: A Gynecologic Cancer Intergroup (GCIG) Trial led by the NCIC CTG.

Status: Recruiting

Phase of Trial: Phase II/III

Latest Information Update: 18 Sep 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

08 Apr 2020 Biomarkers information updated
04 Dec 2013 Accrual to date is 38% according to United Kingdom Clinical Research Network.
10 Nov 2013 Accrual to date is 36% according to United Kingdom Clinical Research Network.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com